HONG KONG, CHINA - EQS Newswire - 15 April 2020 - On 15th April 2020, a fully integrated biopharmaceutical company -- Uni-Bio Science Group Limited (the "Company", together with its subsidiaries, the"Group"; Stock code: 0690.HK) is pleased to announce that its wholly-owned subsidiary Beijing Genetech Pharmaceutical Company Limited (Beijing BKJ), Sinopharm Weiqida Pharmaceutical Company Limited (Sinopharm Weiqida ) and Suzhou Yingli Medical Technology Company Limited (Suzhou Yingli) formed a strategic partnership to improve the industry value chain for the Group product Acarbose (also known as"Boshutai"). According to the agreement, Suzhou Yingli is responsible for the early development of Acarbose active ingredient (API), Sinopharm Weiqida is responsible for Acarbose API industrialization development, manufacturing and supply, and as a result, Beijing BKJ will have at least 10 years stable supply of Acarbose API for product commercialization.


The win-win collaboration structure between Uni-Bio Science, Sinopharm Weiqida and Suzhou Yingli aligns the three companies' incentives, enabling the parties to leverage their respective advantages, closely integrating the upstream and downstream of the industry value chain, enhancing production efficiency to reduce cost, all the while maintaining the high quality of the product. Most importantly, the collaboration facilitates Boshutai to become a future winner of the national drug volume-based procurement. In turn, it will better serve China's diabetes patients by decreasing payment pressure of medical insurance and providing high quality affordable therapeutic options.

Diabetes is one of the core focus areas of the Group. The Group has launched several Diabetes products and others currently under development, including Mitiglinide, Acarbose and GLP-1; the Group's diabetes product pipeline covers different mechanisms of action, providing an integrated therapeutic solution for patients. The Group expects launching Acarbose will add tremendous value for the Group, solidifying a stronger foothold into the diabetes market, as well as developing sales synergy with other diabetes products of the Group. Meanwhile, the close strategic partnership with a leading API manufacturer may expand to other products that could add further value to the Group's future portfolio and business.

Referring to the collaboration, Mr. Kingsley Leung, the Chairman of the Group, said, "The collaboration with Sinopharm Weiqida is crucial for our Acarbose commercialization plan. In the new market conditions in China, cost leadership is the key for any generic drug to succeed. By leveraging each company's strength and closely integrating the industry value chain, we will be able to compete in an RMB 8.4 billion market where only four players presently compete. The math is simple, even if we only win 10% of the market, it is already RMB 840 million sales, which is four times the Group sales in 2019. Unlike the past, the new market dynamics means we don't need to invest in the market, and see a slow ramp up in sales. Simply winning the tender will immediately give us big volumes."

Mr. Miao Ruichun, the President of Sinopharm Weiqida Pharmaceutical, said, "Partnership between Sinopharm Weiqida , Uni-Bio and Suzhou Yingli completely aligns with strategy of Sinopharm Weiqida , to leverage integration advantages of research & development, API and formulation, and helps Sinopharm Weiqida explore the Market Authorization Holder (MAH) system. The partnership will drive parties to achieve great revenue, build great competitive advantages for the product, and develop a solid foundation for the product to gain its market share."

Talk to Media OutReach today

Let Media OutReach help you achieve your communication goals. Send an email to info@media-outreach.com or click below. You will receive a response within 24 hours.

Contact us now